Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 116, Issue 10, Pages 2663-2672Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI28773
Keywords
-
Categories
Funding
- NIA NIH HHS [K08 AG024758] Funding Source: Medline
- NINDS NIH HHS [NS045195, R01 NS045195] Funding Source: Medline
Ask authors/readers for more resources
Kennedy disease, a degenerative disorder characterized by androgen-dependent neuromuscular weakness, is caused by a CAG/glutamine tract expansion in the androgen receptor (Ar) gene. We developed a mouse model of Kennedy disease, using gene targeting to convert mouse androgen receptor (AR) to human sequence while introducing 113 glutamines. AR113Q mice developed hormone and glutamine length-dependent neuromuscular weakness characterized by the early occurrence of myopathic and neurogenic skeletal muscle pathology and by the late development of neuronal intranuclear inclusions in spinal neurons. AR113Q males unexpectedly died at 2-4 months. We show that this androgen-dependent death reflects decreased expression of skeletal muscle chloride channel 1(CLCN1) and the skeletal muscle sodium channel a-subunit, resulting in myotonic discharges in skeletal muscle of the lower urinary tract. AR113Q limb muscles show similar myopathic features and express decreased levels of mRNAs encoding neurotrophin-4 and glial cell line-derived neurotrophic factor. These data define an important myopathic contribution to the Kennedy disease phenotype and suggest a role for muscle in non-cell autonomous toxicity of lower motor neurons.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available